# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barclays analyst Luke Sergott maintains Sotera Health (NASDAQ:SHC) with a Overweight and lowers the price target from $19 to...
Citigroup analyst Patrick Donnelly upgrades Sotera Health (NASDAQ:SHC) from Neutral to Buy and lowers the price target from ...
Jefferies analyst David Windley upgrades Sotera Health (NASDAQ:SHC) from Hold to Buy and raises the price target from $15 to...
Shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) fell sharply during Wednesday’s session after the company announced it con...
RBC Capital analyst Sean Dodge reiterates Sotera Health (NASDAQ:SHC) with a Outperform and maintains $20 price target.